Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Feb 19;3(2):e101.
doi: 10.1038/psp.2013.77.

Evaluating systems pharmacology models is different from evaluating standard pharmacokinetic-pharmacodynamic models

B Agoram  1
Affiliations

Evaluating systems pharmacology models is different from evaluating standard pharmacokinetic-pharmacodynamic models

B Agoram. CPT Pharmacometrics Syst Pharmacol. .

Abstract

Based on the author's recent experience, there appears to be some confusion regarding the steps required to qualify a systems pharmacology model as adequate for the intended purpose. This manuscript outlines the model evaluation approach used in the author's recent publication(1) on the systems pharmacology of a 5-lipoxygenase inhibitor and is an attempt to generate discussion on this topic within the pharmacometrics and systems pharmacology community.

PubMed Disclaimer

References

    1. Demin O., et al. Systems pharmacology models can be used to understand complex pharmacokinetic-pharmacodynamic behavior: an example using 5-lipoxygenase inhibitors. CPT Pharmacometrics Syst. Pharmacol. 2013;2:e74. - PMC - PubMed
    1. Hendriks B. Negative modeling results: a dime a dozen or a stepping stone to scientific discovery. CPT Pharmacometrics Syst. Pharmacol. 2013;2:e48. - PMC - PubMed
    1. Brännmark C., et al. Insulin signaling in type 2 diabetes: experimental and modeling analyses reveal mechanisms of insulin resistance in human adipocytes. J. Biol. Chem. 2013;288:9867–9880. - PMC - PubMed
    1. Landersdorfer C.B., He Y.L., Jusko W.J. Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes. Br. J. Clin. Pharmacol. 2012;73:373–390. - PMC - PubMed
    1. Peterson M.C., Riggs M.M. Predicting nonlinear changes in bone mineral density over time using a multiscale systems pharmacology model. CPT Pharmacometrics Syst. Pharmacol. 2012;1:e14. - PMC - PubMed

LinkOut - more resources